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Abstract
Toll-like receptor (TLR) ligands are being considered as adjuvants for the induction of antigen-specific immune responses, as
in the design of vaccines. Polyriboinosinic-polyribocytoidylic acid (poly I:C), a synthetic double-stranded RNA (dsRNA), is
recognized by TLR3 and other intracellular receptors. Poly ICLC is a poly I:C analogue, which has been stabilized against the
serum nucleases that are present in the plasma of primates. Poly I:C12U, another analogue, is less toxic but also less stable in
vivo than poly I:C, and TLR3 is essential for its recognition. To study the effects of these compounds on the induction of
protein-specific immune responses in an animal model relevant to humans, rhesus macaques were immunized
subcutaneously (s.c.) with keyhole limpet hemocyanin (KLH) or human papillomavirus (HPV)16 capsomeres with or
without dsRNA or a control adjuvant, the TLR9 ligand CpG-C. All dsRNA compounds served as adjuvants for KLH-specific
cellular immune responses, with the highest proliferative responses being observed with 2 mg/animal poly ICLC (p=0.002)
or 6 mg/animal poly I:C12U (p=0.001) when compared with immunization with KLH alone. Notably, poly ICLC—but not
CpG-C given at the same dose—also helped to induce HPV16-specific Th1 immune responses while both adjuvants
supported the induction of strong anti-HPV16 L1 antibody responses as determined by ELISA and neutralization assay. In
contrast, control animals injected with HPV16 capsomeres alone did not develop substantial HPV16-specific immune
responses. Injection of dsRNA led to increased numbers of cells producing the T cell–activating chemokines CXCL9 and
CXCL10 as detected by in situ hybridization in draining lymph nodes 18 hours after injections, and to increased serum levels
of CXCL10 (p=0.01). This was paralleled by the reduced production of the homeostatic T cell–attracting chemokine CCL21.
Thus, synthetic dsRNAs induce an innate chemokine response and act as adjuvants for virus-specific Th1 and humoral
immune responses in nonhuman primates.
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Introduction
Effective vaccines against infections caused by intracellular
pathogens including HIV infection, malaria, or tuberculosis
most likely will need to induce strong cellular and humoral
immune responses [1]. Current vaccine strategies under develop-
ment are based on prime-boost immunizations, such as vaccina-
tion with plasmid DNA followed by booster injections with
replication-incompetent viral vectors (e.g., adenoviruses or poxvi-
ruses), with both DNA and viruses encoding immunogenic
proteins of the pathogen [2]. There is concern that these strategies
may be insufficiently immunogenic and protective, so alternative
vaccine approaches are under development [3,4]. While protein
based vaccines allow the delivery of large amounts of immuno-
genic vaccine antigens, particularly when targeted to antigen
presenting dendritic cells (DCs) [5], these vaccines require the
PLoS Pathogens | www.plospathogens.org 1 April 2009 | Volume 5 | Issue 4 | e1000373identification of appropriate adjuvants [6], which may act by
differentiating the DCs to elicit strong immunity [7–10]. Monkeys
are being used as an animal model to develop AIDS vaccines and
are likely to be a valuable preclinical model to identify adjuvants
and understand their mode of action.
Currently the most widely used adjuvant is aluminum
hydroxide. It predominantly induces Th2 immune responses
[11], and as such may be inappropriate for HIV or tuberculosis
vaccines or for immune therapy of tumors related to infection by
human papillomaviruses (HPV). Ligands for pathogen recognition
receptors, e.g., Toll-like receptor (TLR) ligands, can stimulate cells
of the innate and adaptive immune systems and have therefore
been proposed as promising adjuvant candidates [12,13]. We have
previously studied the effects of TLR9 ligands, i.e., CpG-A and
CpG-B, on the induction of protein-specific immune responses in
nonhuman primates. However, we did not observe strong CD4
+ T
cell-mediated immune responses as indicated by T cell prolifer-
ative assays [14]. This may in part be due to the lack of TLR9
expression in myeloid primate DCs [15], which can be valuable
for the priming of naı ¨ve T cells and the induction of cellular
immune responses [16,17]. In this study, we have focused on
synthetic double stranded RNA (dsRNA) compounds as adjuvants.
They can be recognized by both TLR3 [18] and the melanoma
differentiation-associated gene-5 (MDA-5) [19], pattern recogni-
tion receptors that are expressed by many cell types and are
involved in anti-viral immune responses [20].
In mice, polyriboinosinic-polyribocytoidylic acid (poly I:C) has
long been known as a strong IFN-a inducer and provides anti-viral
and adjuvant activity [21,22]. Poly I:C also works as a mucosal
adjuvant for the induction of humoral and cell-mediated immune
responses [23–25]. MDA-5 is important for the IFN response
induced by poly I:C [26,27].
In primates, poly I:C is a less effective IFN-a inducer, most
likely due to nucleases, which reduce the biostability of poly I:C
and are reported to be more prevalent in the serum of primates
than rodents [28]. A complex of poly I:C with poly-L-lysine and
carboxymethylcellulose (poly ICLC), however, is five to 10 times
more resistant to hydrolysis by RNAse in primate serum than the
parent poly I:C and induces significant levels of interferon in
monkeys under conditions in which poly I:C itself induces no
interferon [29,30]. Poly ICLC possesses anti-viral activity against a
variety of viruses in monkeys [31–33] and chimpanzees [34], and
also inhibits malaria infection of macaques [35]. Furthermore, it
has shown potent adjuvant activity on the induction of humoral
immune responses in the nonhuman primate models of Venezue-
lan equine encephalomyelitis virus and swine influenza virus
[36,37]. In humans, dose-dependently, mild to moderate side
effects of poly ICLC were observed in a number of phase I and II
studies conducted in children and adults [38–45]. Another
synthetic dsRNA, poly I:C12U (Ampligen), supports the induction
of broad antiviral immune responses in mice [46,47], shows low
toxicity in humans [48], and should therefore also be considered as
an adjuvant in human vaccine trials. To date, no studies have been
reported on the potential of synthetic dsRNA to augment cellular
immunity in primates.
We therefore have performed studies in rhesus macaques to
address the impact of dsRNA on the induction of protein-specific
immune responses. As a prelude to studies with protein based
vaccines, we selected keyhole limpet hemocyanin (KLH). In
contrast to a previous study where TLR7/8 and TLR9 ligands
have been used as adjuvants for cellular immunity in rhesus
macaques [49], we injected the dsRNA plus KLH in aqueous
solution without additional emulsification in water-in-oil adju-
vants, such as Montanide, to minimize the risk of undesired side-
effects at the site of injection. To confirm that the adjuvant effect
of dsRNA is also manifest in the context of the injection of viral
proteins, we injected some animals with the major capsid protein
(L1) of HPV16 with or without poly ICLC. HPV16 is the major
carcinogenic genotype of HPV in most countries and involved in
about 50% of the cases of cervical cancer worldwide [50].
Recently, prophylactic vaccines against HPV16 have been
marketed that consist of L1 virus-like particles (VLPs) and induce
neutralizing antibodies that efficiently protect against persistent
HPV infection and premalignant cervical lesions [51]. However,
therapeutic vaccines for the use in individuals who are already
infected will need to induce cellular immunity, most likely against
the E6/E7 antigens of HPV. Subunits of VLPs (pentameric
capsomeres) have potential advantages over VLPs, i.e., higher
stability and reduced production costs but their immunogenicity
has not yet been evaluated in nonhuman primates.
To monitor also the innate response to dsRNAs, we
concentrated on the rapid innate production of CXCL9 (MIG)
and CXCL10 (IP-10) chemokines, which are induced by dsRNA
[52] as well as CCL21 (SLC), which attracts naı ¨ve T lymphocytes
and DCs [53]. Here we show that dsRNAs act as adjuvants for the
induction of innate and adaptive cellular and humoral immunity
in nonhuman primates.
Results
Synthetic dsRNAs are effective adjuvants for the
induction of protein-specific cellular immune responses
Poly ICLC has adjuvant activity on the induction of humoral
immunity at doses as low as 0.1 mg/kg [37]. Since we assumed
that higher doses might be required for the induction of cellular
immune responses, we immunized rhesus macaques subcutane-
ously (s.c.) with KLH and either poly ICLC (0.5 mg/kg body
weight; 6 animals), poly I:C (0.5 mg/kg; 4 animals), or without
adjuvant (4 animals). To monitor the development of T cell
immunity, we cultured peripheral blood mononuclear cells
(PBMC) with or without KLH and determined whether
immunization resulted in T cell proliferative responses to the
Author Summary
Novel adjuvants that facilitate the induction of strong
cellular immunity could be of help in the design of vaccine
strategies to combat infections such as HIV or tuberculosis.
Our immune cells possess archaic receptors recognizing
structures of infectious pathogens, and the interaction of
these receptors with their ligands results in an activation of
the immune system. Here we exploited synthetic forms of
one of these ligands, i.e., dsRNA, to define an adjuvant for
the induction of cellular immune responses in primates.
We injected model and viral proteins together with three
different forms of dsRNA subcutaneously (s.c.) in rhesus
macaques, and all compounds served as adjuvants for the
induction of cellular immunity without the incidence of
major side effects. These adjuvant effects depended on the
adjuvant dose and coincided with profound alterations in
the chemokine production in the draining lymph nodes.
dsRNA also helped to induce cellular and humoral immune
responses against capsomeres of low immunogenicity
derived from the human papillomavirus 16, the causative
agent in about 50% of all cases of cervical cancer
worldwide. Therefore, formulations involving synthetic
dsRNA are promising candidates for development of novel
vaccines.
dsRNAs Are Adjuvants in Primates In Vivo
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3H thymidine incorporation assays. Peak
stimulation indices (SI; KLH-induced proliferation divided by
proliferation in medium alone) were significantly higher
(p=0.040) in animals injected with poly ICLC (week 0,
1.9361.38; peak, 23.0068.02) compared with KLH alone (week
0, 3.2861.55; peak, 8.9767.47), individual maximum prolifera-
tive responses are shown in Table S1. The kinetics of the responses
are shown in the Figure S1 and reveal significantly stronger
proliferative responses in poly I:C co-injected animals than in
controls six weeks post injection (p=0.03). Thus, KLH-dependent
proliferation of PBMCs was induced with poly ICLC or poly I:C
by the s.c. route.
The poly I:C analogue poly I:C12U requires TLR3 to be active
in vivo [54,55] and shows little toxicity in humans [48]. Like poly
I:C and in contrast to poly ICLC, it is not stabilized against
primate serum nucleases. We therefore compared the effectiveness
of poly I:C12U to poly ICLC in a separate study, using fixed
standardized doses per animal rather than adjustment to body
weight. To study the effects of dsRNA on cellular immune
responses in more detail, we used a carboxyfluorescein diacetate
succinimidyl ester (CFSE) dilution assay, which allows the separate
evaluation of CD4
+ and CD8
+ T cells (Figure 1A). KLH at
200 mg/animal was administered to five animals each either alone
or together with 2 or 6 mg poly I:C12U or 2 mg poly ICLC per
animal (i.e., 0.27 to 0.44, 1.00 to 1.13, and 0.33 to 0.43 mg/kg,
respectively). The dose of 2 mg per animal has been used in
previous studies on TLR agonists as vaccine adjuvants in monkeys
[49] and thus facilitates comparison between studies of different
adjuvant compounds. KLH-specific CD4
+ T-cell proliferation at
week 2 after immunization was significantly higher when KLH
was given with either 6 mg poly I:C12U (p=0.001) or 2 mg poly
ICLC (p=0.002) whereas at that time point no significant
difference to KLH alone was observed after the injection of
2 mg poly I:C12U (p=0.16; Figure 1B). The effect of immuniza-
tion with poly I:C12U or poly ICLC on proliferative responses was
sustained over 6 weeks, and there was a significant difference also
for the 2 mg poly I:C12U group over KLH alone at this time point
(p=0.013; Figure 1B). Thus, all three synthetic dsRNA com-
pounds that we tested could serve as adjuvants for the induction of
protein-specific T-cell proliferation in primates.
To examine possible dose-dependent adjuvant effects of poly
ICLC, we compared in a prime-boost experiment the effects of
0.5 mg/kg body weight with those of 0.1 mg/kg body weight,
which is still sufficient for the induction of humoral immune
responses [37]. After the first immunization increased KLH-
specific CD3
+CD4
+ T cell proliferative responses were seen in
both animals immunized with 0.5 mg poly ICLC/kg, and
CD3
+CD4
2 T cells (as a surrogate for CD8
+ T cells) were
expanded to a similar extent (Fig. S2A). CD4
+ and CD4
2 T cell-
proliferative responses were less pronounced after the primary
immunization together with the lower 0.1 mg/kg dose of poly
ICLC (Figure S2B). Booster immunization at week 14 enhanced
the proliferative CD4
+ T cell responses in the animal 13404
immunized with 0.5 mg poly ICLC/kg (Figure S2A) and in the
animal 13406 receiving the lower dose of poly ICLC (Figure S2B).
Therefore, 0.5 mg/kg of poly ICLC might be more active as an
adjuvant for cellular immunity than lower doses.
Injection of poly ICLC supports the induction of HPV-
specific Th1 and humoral immune responses
To confirm that dsRNA analogues also serve as adjuvants in the
context of a clinically relevant viral antigen, we injected s.c. six
animals each with a low dose of HPV16 L1 capsomeres (10 mg)
with or without 2 mg of poly ICLC. Another six animals were
injected with 2 mg of the TLR9 ligand CpG-C (ODN 2396),
which supports the induction of protein-specific cellular immune
responses in monkeys when injected in a water-in-oil emulsion
[49]. We selected the L1 pentamers rather than the complete
virus-like particles (VLP; 360 molecules of L1), since capsomeres
are promising candidates for 2
nd generation vaccines but their
immunogenicity in nonhuman primates has not yet been
evaluated. The capsomeres were obtained by expression of a
modified L1 protein in baculovirus-infected insect cells [56]. In the
immune assays, we re-stimulated PBMCs with HPV16 VLPs and
used mouse norovirus VLPs (A447) generated in the same
expression system as a negative control antigen. All animals were
boosted with a second injection of antigen +/2 adjuvant eight
weeks later.
Numbers of IFN-c secreting cells in the peripheral blood were
determined by ELISPOT assay. At week 2, we detected increased
numbers of HPV-specific, IFN-c secreting cells in PBMCs from 4
out of 6 animals (Figure 2A) injected with antigen plus poly ICLC,
and the responses waned in all animals by week four. Two weeks
after the booster injection (at week 10 after the first injections),
however, all six animals injected with antigen together with poly
ICLC had developed HPV-specific, IFN-c secreting cells, which
also were maintained two weeks later (week 12) and still present in
3 animals at week 19. In contrast, IFN-c secreting cells were
detectable at elevated numbers in only one of the CpG-injected
monkeys (animal 13928) four weeks after the first injection and this
response could not be boosted by the second injection. None of the
control animals showed substantial numbers of HPV-specific IFN-
c secreting cells, neither following the first nor the booster injection
(Figure 2A). The background responses against A447 might be
induced by contaminating protein fractions derived from the
expression system, in which both antigens, i.e., HSV16 L1
capsomeres and A447, had been generated.
When we assessed T cell proliferation in CFSE assays, we found
significantly enhanced HPV-specific CD4
+ T-cell proliferative
responses in the poly ICLC-injected monkeys four weeks after the
second application of antigen (p=0.008) (Figure 2B). Figure 2B
depicts the proliferation of CD3
+CD8
2 cells, re-stimulated for the
last 6 h of the assay with peptide pools 1–4. Similar results
(p=0.012, week 12) were obtained with cells re-stimulated for the
final 6 h with pools 5–8 (data not shown). At week 19, proliferative
responses did not differ significantly in poly ICLC-injected and
control animals.
To further characterize the Th cell responses, we determined
the concentrations of IFN-c, IL-4, and IL-17 in supernatants
collected from re-stimulated PBMCs 2 d after setting up the
assays. We used ELISAs for the detection of monkey cytokines or,
in the case of IL-17 an ELISA for the detection of the human
protein but known to cross-react with monkey IL-17 [57].
Following the booster injection at week 8, we detected significantly
more IFN-c in the supernatants of cells collected from poly ICLC-
injected animals than in those of cells from control animals and
these responses were sustained until week 19 (Figure 2C). In
contrast, we were unable to detect IL-4 or IL-17 in the
supernatants from assays set up with PBMCs from either group
of animals. Thus, poly ICLC supports the induction of HPV-
specific Th1 immune responses, i.e., CD4
+ T cell proliferative
responses and IFN-c secretion.
We also determined the humoral immune responses induced by
the injection of HPV16 L1 capsomeres with or without adjuvants.
Injection of poly ICLC or CpG-C resulted in up to 1000fold
increased titers of binding antibodies (measured by ELISA)
compared with control animals (Figure 3A; p,0.01 for both
adjuvants for weeks 4, 8, 10, and 12), and at weeks 4, 8, and 10,
dsRNAs Are Adjuvants in Primates In Vivo
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(p,0.05 for week 4, p,0.01 for weeks 8 and 10). The individual
antibody titers of all animals are shown for all points in time in the
Table S2. In addition, we performed neutralization assays using
the serum samples collected 12 weeks after first immunization and
HPV16 pseudovirions as targets. Sera of the animals from both
adjuvant groups showed considerable neutralizing activity while
samples from the control animals were not able to neutralize the
activity of the pseudovirions in our assay (Figure 3B). Poly ICLC
injected animals showed stronger responses than monkeys that had
received CpG-C (p=0.03 for serum dilutions of 1:1000). There
was a good correlation between ELISA and neutralization titers in
the sera of the individual animals (Figure S3). Therefore, while
CpG-C mainly affects the induction of antibodies, poly ICLC acts
as adjuvant for both humoral and cellular immunity.
Injection of KLH plus synthetic dsRNA induces an innate
chemokine response in the T cell areas of draining lymph
nodes and serum
Since we have previously observed that poly I:C activates
monkey DCs [58], immunohistochemistry was performed to
determine the number and activation status of DCs present in
lymph nodes taken prior to immunization and at 18 h after
injection of poly ICLC. The numbers of phenotypically immature
(CD1a
+) and mature (CD83
+ or CD208
+) DCs varied between
animals but did not show a clear decrease or increase after
immunization (Figure S4).
Draining inguinal lymph nodes were also analyzed for
CXCL10, CXCL9, and CCL21 by in-situ hybridization and
immunohistochemistry. In comparison to control lymph nodes
removed before immunizations, elevated expression of CXCL10
(Figure 4A and 4B) and CXCL9 (Figure 4C and 4D) was detected
in the T cell areas of draining lymph nodes at 18 hours after
immunization. Chemokine mRNA expression correlated with
protein expression detected by immunohistochemistry (insets in
Figure 4). Expression of CCL21 mRNA (Figure 5A) and protein
(Figure 5B and 5C) 18 hours after immunization was markedly
decreased in draining lymph nodes compared with control lymph
nodes obtained before immunization. Thus, the innate response to
dsRNA is detectable in lymph node cells.
The administration of poly ICLC or poly I:C together with
KLH led to a significant increase of serum levels of CXCL10
(Figure 6A; p=0.001 for both compounds at 18 or 24 h).
Furthermore, 48 h after immunization, serum levels of CXCL10
were significantly higher in poly ICLC- than in poly I:C-injected
monkeys (p=0.027). Like poly I:C at 0.5 mg/kg, poly I:C12Uo r
lower doses of poly ICLC (0.1 mg/kg) induced increased CXCL10
levels, which were less sustained (Figure 6B and 6C).
We detected increased CXCL9 serum levels in animals injected
with poly I:C or poly ICLC (0.5 mg/kg), and there were minor
changes in CXCL9 concentrations in monkeys receiving KLH
alone (Figure 6D). No changes of CXCL9 serum concentrations
were observed when 0.1 mg/kg poly ICLC were administered
(data not shown). At 6, 24, or 48 h after infection, no significant
differences in serum levels of IFN-a, IFN-c, TNF, IL-12p40, and
CCL3 (MIP-1a) were observed between groups receiving KLH
alone or together with dsRNA (data not shown). We were not able
to detect considerable serum concentrations of IFN-a at any point
in time including 1 h post injection.
CXCL10 production by rhesus macaque DCs activated
through dsRNA
Since immunohistochemistry and in-situ hybridization revealed
that CXCL10 was mainly produced in the T cell-areas of the
draining lymph nodes (Figure 4), we considered DCs as a potential
source for this chemokine in vivo. Unfortunately, double-labeling
with DC identifying mAbs was not possible on formalin-fixed
specimens. We therefore tested whether dsRNA may directly
induce CXCL10 secretion by highly purified rhesus macaque DCs
in vitro. When monocyte-derived monkey DCs were incubated
with poly ICLC at two different concentrations (50 and 200 mg/
ml), significantly elevated CXCL10 concentrations were detecta-
ble 48 h later in the cell culture supernatants (p=0.002 compared
to un-stimulated controls), and both doses of of poly ICLC
induced comparable levels of CXCL10 (Figure 7). Thus, primate
DCs produce CXCL10 upon stimulation with synthetic dsRNA,
making DCs one of the candidate sources of CXCL10 observed in
the draining lymph nodes.
Discussion
This study shows that s.c. injection of synthetic dsRNA, i.e., poly
I:C, poly ICLC, or poly I:C12U supports the induction of cellular
immune responses toprotein antigensinnonhuman primates. These
responses could also be boosted by a second injection of antigen
together with dsRNA. We observed antigen-specific T cell
proliferation of CD3
+CD4
+ and CD3
+CD4
2 Tc e l l s .H i g hb u t
nontoxic doses (toxicity starts in M. mulatta at i.v. doses .2m g / k g ,
i.m. or s.c. injections are better tolerated than i.v. injections;
unpublished observations) of poly ICLC (0.5 mg/kg or 2 mg/
animal)mightbemorepotentthanlowerdoses(#0.1 mg/kg).Using
HPV16 capsomeres at low doses (10 mg/animal) as a relevant viral
antigen with low immunogenicity, we also showed that poly ICLC,
but not CpG-C (which supported the induction of humoral
responses, however), supports the induction of HPV16-specific
Th1 responses. The lack of effect of CpG-C in our system compared
to other studies where the same compound helped to elicit cellular
immunity in nonhuman primates is most likely due to the fact that
we injected the antigens in PBS, while others injected CpG-C and
antigens in the synthetic water-in-oil emulsion, Montanide [49].
Amongst the three different formulations of synthetic dsRNA, poly
ICLC appears to possess the most potent adjuvant activity on the
induction of cellular immune responses. Subsequent studies will
show whether it will help to induce protective immune responses
against other pathogens, e.g., SIV.
Both adjuvants supported the induction of humoral
immune responses, including neutralizing antibodies. Therefore,
Figure 1. Induction of KLH-specific proliferation by immunization with KLH plus poly ICLC or poly I:C12U. (A) Live cells in a T cell gate
(SSC
low cells) were analyzed using anti-CD3 PerCP- and anti-CD4 or anti-CD8 APC-conjugated mAbs. CD3
+CD4
+ and CD3
+CD4
2, or CD3
+CD8
+ and
CD3
+CD8
2 cells, respectively, were further analyzed regarding their CFSE expression. The indicated percentages are calculated relative to the number
of gated cells. (B) KLH (200 mg) was administered either alone or in combination with 2 mg poly ICLC, 2 mg poly I:C12U, or 6 mg poly I:C12U per
animal (five animals per group). CFSE-dilution was used to assess KLH-specific proliferation of CD3
+CD4
+ T cells before as well as 2 and 6 weeks after
immunization. Background proliferation (percentage of CFSE
low cells in medium alone) was subtracted from the percentage of CFSE
low cells after
stimulation with 100 mg/ml KLH for 6 days, and means6SD for each group are presented. * Statistical differences at 2 weeks: 6 mg poly I:C12U versus
KLH alone (p=0.001), 2 mg poly ICLC versus KLH alone (p=0.002), 2 mg poly I:C12U versus KLH alone (p=0.16); at 6 weeks: 2 mg poly I:C12U versus
KLH alone (p=0.013).
doi:10.1371/journal.ppat.1000373.g001
dsRNAs Are Adjuvants in Primates In Vivo
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adjuvants currently used in vaccine formulations, e.g., alum,
and investigate whether its co-application might allow fewer
injections than required today for the currently licensed vaccine
formulations.
In order to understand the activity of dsRNA, we examined the
innate response since this includes events that can improve the
function of antigen presenting DCs and T cells. Surprisingly, we
did not detect the expected increase of serum IFN-a shortly after
injection of poly I:C or poly ICLC. This might be due to the s.c.
Figure 2. Induction of HPV-specific Th1 immune responses by injection of HPV16 L1 protein and poly ICLC. HPV16 capsomeres (10 mg/
animal) were injected either alone or in combination with 2 mg poly ICLC or 2 mg CpG-C per animal at weeks 0 and 8 (six animals per group), and
immune responses were monitored in triplicates in IFN-c ELISPOT assays (A), CFSE dilution assays gated on CD4
+ T cells (B), and IFN-c concentrations
in supernatants of re-stimulated PBMCs (C), at baseline (pre) and the indicated points in time after the first immunizations. At week 19, only five of the
six poly ICLC-injected animals could be analyzed for proliferation and IFN-c secretion. (A) To determine the numbers of HPV-specific IFN-c secreting
cells, PBMCs were re-stimulated with HPV or control antigen (A447) at 1.25 mg/ml for 20 hours, the ELISPOT plates developed, and the spot numbers
counted and extrapolated to 10
6 PBMCs (HPV16, black bars; A447, light grey bars). Average spot numbers of background responses (to A447) plus
twice the standard deviation were considered positive (*). (B) HPV-specific proliferative responses were determined using CFSE-labeled PBMCs
expanded for 6 days in the presence of HPV16 or control antigen (A447) at 1.25 mg/ml and re-stimulated with peptide pools 1–4 (B) or 5–8 (data not
shown) for the final 6 hours of the assay. Data shown as mean %CFSE
low (HPV16) minus background proliferation (%CFSE
low with A447)6SEM. *
p=0.008. (C) PBMCs were re-stimulated with HPV16 or control antigen (A447) at 1.25 mg/ml for 2 days, supernatants were collected, and IFN-c
concentrations determined using a monkey IFN-c specific ELISA assay. Data shown as mean IFN-c secretion (pg/ml) by cells re-stimulated with HPV16
minus background secretion (by cells incubated in the presence of A447)6SEM. * p=0.033 at week 10, p=0.031 at week 12, and p=0.014 at week
19.
doi:10.1371/journal.ppat.1000373.g002
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high serum interferon levels [30], the s.c. application of dsRNA
may lead to a more protracted release from the site of injection
and a delayed bioavailability. In mice, type I interferon induced by
poly I:C has been shown to be essential for its adjuvant effect on
humoral immunity and isotype switching [59], and it also seems
essential for TLR3-mediated cross-priming of CD8
+ T cells [60–
62]. Likewise, type I interferon is critical for the CD8
+ T cell
expansion induced by TLR agonists in combination with CD40
[63]. Poly I:C and poly ICLC induce proliferation of CD8
+ T
cells, both have been shown to be effective as an adjuvant for the
induction of specific CD8
+ T cell responses in mice [64–66], and
this effect partially depends on NK cells [67]. Thus, poly I:C, and
most likely also poly ICLC, support the induction of CD8
+ T cell
responses, and the KLH-specific responses expressed by
CD3
+CD4
2 T cells observed by us might reflect true CD8
responses.
In contrast to our inability to detect IFN-a in the serum in
response to dsRNA, we did detect enhanced levels of CXCL10.
These were sustained over 48 hours in animals injected with
0.5 mg/kg poly ICLC but decreased more rapidly in monkeys
following injection of lower concentrations of poly ICLC, 0.5 mg/
kg poly I:C, or a comparable dose (2 mg/animal) of poly I:C12U.
This may reflect the reduced biostability of the nonstabilized poly
I:C and poly I:C12U compared with that of poly ICLC as
described before [29,30]. CXCL10 is known for its activity to
attract effector Th1 cells through interaction with its receptor
CXCR3 at sites for the expression of Th1 immune responses [68],
e.g., rejection of allografts or the inflammatory response upon
mycobacterial infection [69,70]. CXCL10 is also required for
resistance to protozoan or viral pathogens [71,72]. Studies in mice
revealed additionally that CXCL10 is secreted early (e.g., earlier
than CXCL9, which we did not detect at the same levels in the
serum as CXCL10) [73], and stimulates T cell proliferation [74].
In fact, CXCL10-deficient mice have impaired T cell responses
following primary immunization with exogeneous protein antigen
indicating a role for CXCL10 in effector T cell generation [75].
Since CXCR3 also is induced early in CD4 T lymphocyte
differentiation [76], the literature suggests an enhancing role for
CXCL10 in both the expression and induction of Th1 immune
Figure 3. Both poly ICLC and CpG-C act as adjuvants for the induction of HPV16-specific binding and neutralizing antibodies. HPV16
capsomeres (10 mg/animal) were injected either alone or in combination with 2 mg poly ICLC or 2 mg CpG-C per animal at weeks 0 and 8 (six animals
per group), and L1-specific antibodies in plasma samples were measured (A) by ELISA at baseline (pre) and the indicated points in time after the first
immunization, and (B) by neutralization assays at week 12. Data given as mean titers +/2 SD (A), and as the percentage of neutralization of
pseudovirions by serum samples at the dilutions indicated [(B), line, median; *, individual animals)], measured by reduction of SEAP activity (see
Materials and Methods) and compared to controls of untreated pseudovirions.
doi:10.1371/journal.ppat.1000373.g003
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in serum CXCL10 after injection of CpG-A or CpG-B [14], these
concentrations were around ten-fold lower than in animals
injected with 0.5 mg/kg poly ICLC. Since both the two forms
of CpGs and low doses of poly ICLC had only marginal adjuvant
effects on the induction of cellular immunity, high and sustained
serum levels of CXCL10 after injection of an adjuvant seem to be
indicative of its ability to support the induction of cellular immune
Figure 4. Upregulation of CXCL10 and CXCL9 in draining lymph nodes following injection of poly ICLC. Expression of CXCL10 (A,B) and
CXCL9 (C,D) mRNA (in situ hybridization) and protein (insets) in control lymph nodes before (left panels) and in draining lymph nodes (right panels)
18 hours after KLH-immunization with 0.5 (A,C) or 0.1 mg/kg (B,D) poly ICLC, respectively. The presence of chemokine mRNA is shown by the black
dots in the T cell area (1006 magnification). Cells positive for chemokine protein expression are visible in red (insets: 4006 magnification).
Immunohistochemistry was performed on sections consecutive to the one in which in situ hybridization was performed to confirm protein
expression. Data are representative for two animals for each dose of poly ICLC.
doi:10.1371/journal.ppat.1000373.g004
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inhibits TLR-induced production of CXCL10 [77].
Expression of CXCL9 and CXCL10 was primarily in the T cell
areas of the draining lymph node. Thus, DCs should be
considered as a potential source of these chemokines, since they
are abundant in this area of the lymph node. We show that
monocyte-derived DCs produce CXCL10 upon activation with
dsRNA, which suggests a direct role of these cells in the
production of the pro-inflammatory chemokines and induction
of cellular immune responses in our system. Monkey DCs express
TLR3 (manuscript in preparation) and can be activated by poly
I:C [58], so pattern recognition receptors on DCs likely contribute
to the observed adjuvant effects of dsRNA for CD4
+ T-cell
proliferation. Synthetic dsRNA, however, may also target and
activate other TLR3
+ or TLR3
2 leukocyte subsets. In vitro, it
activates human NK cells [78,79], c/d TCR
+ T cells [80], CD8
+
a/b TCR
+ T cells [81], and also monocytes/macrophages, which
are TLR3
2 [82,83]. These cells (or the corresponding cells in
lymphoid tissues) could contribute to its adjuvant activity, e.g.,
through the secretion of pro-inflammatory cytokines and notably
type I and II interferons. While it remains to be determined
whether dsRNA can promote survival of primate CD4
+ T cells as
recently shown for murine cells [84], analyses of human blood
leukocytes shortly after poly ICLC injection revealed increased
percentages of CD4
+ T cells, but also effects on the activity of NK
cells and the frequency of HLA-DR
+ cells [85]. Nevertheless, cells
other than leukocytes including keratinocytes and neurons also can
produce type I interferons and other pro-inflammatory cytokines
upon stimulation with poly I:C [86,87].
After injection of dsRNA, we observed a down-regulation of the
homeostatic chemokine CCL21, which attracts CCR7
+ cells, such
as DCs and naı ¨ve T cells, to lymph nodes. In agreement with the
advuvant effect of poly ICLC on the induction of HPV-specific
Th1 immune responses shown in the present study, this process
has recently been described for the early phase of the induction of
Th1 but not Th2 immune responses in mice and is controlled by
Figure 5. Downregulation of CCL21 in draining lymph nodes 18 hours after immunization with KLH plus poly ICLC. (A) Expression of
CCL21 mRNA (determined by in situ hybridization) in control lymph nodes before (black dots, left panel) and in draining lymph nodes (right panel)
18 hours after KLH-immunization with 0.5 mg/kg poly ICLC; in situ hybridization, 1006 magnification. (B,C) Cells positive for CCL21 protein
expression (determined by immunohistochemistry) are visible in brown in the T cell areas of control lymph nodes (left panels) and of draining lymph
nodes (right panels) after immunization with KLH plus 0.5 mg/kg (B) or 0.1 mg/kg (C) poly ICLC; 4006magnification.
doi:10.1371/journal.ppat.1000373.g005
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using HPV16 capsomeres as viral protein antigen with relevance
to the human system. Animals injected with HPV together with
poly ICLC developed Th1 immune responses characterized by
antigen-specific T cell proliferation and IFN-c secretion in the
absence of detectable IL-4 or IL-17 production.
In conclusion, dsRNA compounds induce the innate production
of CXCL10 in the draining lymph nodes and high CXCL10
concentrations in the serum early after injection, and these
compounds are effective adjuvants for the induction of adaptive
pathogen-specific T cell and humoral immune responses.
Materials and Methods
Animals and immunizations
Healthy young adult male and female rhesus macaques (Macaca
mulatta) housed at the German Primate Center (Deutsches
Primatenzentrum, Go ¨ttingen, Germany) were used. The animals
were antibody negative for simian T-lymphotropic virus type 1,
simian D-type retrovirus, and simian immunodeficiency virus. All
animal care operations were in compliance with the guidelines of
the German Primate Center and approved by the local authorities.
For immunizations and collection of blood samples animals were
sedated with ketamine. For the removal of lymph nodes, a deeper
anesthesia consisting of a mixture of xylazine, atropine, and
ketamine was used. 200 mg endotoxin-free KLH (Calbiochem,
San Diego, CA, USA) or 10 mg HPV 16 capsomeres alone or in
combination with either poly I:C (Invivogen/Cayla, Toulouse,
France), poly ICLC (Hiltonol, Oncovir, Washington, D.C.), poly
I:C12U (Ampligen, Celldex Therapeutics, Bloomsbury, NJ, USA),
or CpG-C (ODN 2396, generously provided by Coley Pharma-
ceutical Group, Wellesley, MA, USA) were administered bilater-
ally s.c. at doses indicated in the text at volumes between 1.0 and
2.0 ml, partially diluted in PBS, by injecting close to the inguinal
lymph nodes. All animals remained well following the application
of dsRNA plus antigen and no local signs of inflammation apart
from transient lymph node swellings and mils hyperemia were
observed at sites of injection.
Blood samples were drawn at 0, 1 or 6, 18 or 24, and 48 h after
injections for measurements of serum cytokine and chemokine
concentrations. To determine humoral and cellular immune
responses additional blood samples were drawn at points in time
indicated. Axillary lymph nodes were removed before the
immunizations, and 18 h after the injections one draining lymph
Figure 6. dsRNA-induced CXCL10 and CXCL9 in serum. (A) Mean serum levels (6SD) of CXCL10 after immunization of animals with either KLH
alone (n=4), KLH+0.5 mg/kg poly I:C (n=4 animals), or KLH+0.5 mg/kg poly ICLC (n=6 animals). (B) The effect of lower doses of poly ICLC on CXCL10
serum levels was assessed in two animals immunized with 0.1 mg/kg. (C) Mean serum levels (6SD) of CXCL10 after immunization of five animals per
group with either KLH alone, KLH+6 mg poly IC12U, KLH+2 mg poly IC12U, or KLH+2 mg poly ICLC. (D) Serum levels of CXCL9 after immunization with
either KLH alone (n=2, dotted lines), KLH+0.5 mg/kg poly I:C (full lines, open symbols), or KLH+0.5 mg/kg poly ICLC (full lines, full symbols).
Chemokine levels were determined at the indicated points in time; *, p=0.027; **, p#0.001.
doi:10.1371/journal.ppat.1000373.g006
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were divided in two parts. One part was fixed in 4% neutral-
buffered formalin overnight and embedded in paraffin. The other
halves were embedded in tissue-freezing medium (Leica, Nussloch,
Germany), snap-frozen in liquid nitrogen, and stored at 270uC
until use.
Purification of HPV16 L1 particles
HPV16 L1 capsomeres were produced using recombinant
baculoviruses containing the mutated L1 (L1_2xCysM:
C175A+C428A) as described previously [56]. In short, High Five
insect cells (Invitrogen, Germany) were infected with recombinant
baculoviruses and harvested by centrifugation. Proteins were
extracted by sonification from cell pellets resupended in 20 ml of
extraction buffer (5 mM MgCl2, 5 mM CaCl2, 1 M NaCl, 0.01%
Triton 6100, 20 mM Hepes pH 7.4 and 1 mM PMSF). The
cleared lysate was loaded on a two-step gradient consisting of (30%
w/v) sucrose and CsCl (58% w/v), followed by a centrifugation at
96,500 g at 10uC for 3 h in a SW32 rotor (Beckman Ultracen-
trifuge). The interphase between the sucrose and CsCl and the
complete CsCl layer were centrifuged again in Quickseal tubes
(Beckman, USA) for 16–18 h at 20uC at 184,000 g in a Sorval
TFT 65.13 rotor. Fractions of 1 ml fractions were collected and
the L1 containing determined by antigen-capture ELISA and
western blot analysis and the structure of the particles was
characterized by electron microscopy [89]. The control antigen
(mouse norovirus VP1 VLPs) were generated by the identical
protocol. The VP1 clone was kindly provided by W. Nicklas,
DKFZ Heidelberg.
T cell assays
Standard proliferation assays were set up with 1610
5 PBMCs/
well in 96-well round-bottom trays (Nunc) with KLH (100 mg/ml)
in cell culture medium consisting of RPMI 1640, supplemented
with 2 mM L-glutamine, penicillin (100 U/ml)-streptomycin
(100 mg/ml), 10 mM HEPES (all GIBCO, Invitrogen, Karlsruhe,
Germany), 50 mM 2-mercaptoethanol (Sigma), and 10% heat-
inactivated FCS (Biochrom, Berlin, Germany). Controls included
PBMCs in medium alone and PBMCs stimulated with 5 ng/ml
staphylococcal enterotoxin B (SEB; Alexis Corp., Lausen,
Switzerland). All conditions were set up in triplicates and cultures
were incubated at 37uC and 5% CO2. Supernatants were
harvested on day 2 and frozen at 280uC for analyses of cytokine
concentrations.
3H-thymidine (1 mCi/well, NEN, Perkin Elmer,
Boston, MA, USA) was added to the wells on day 3 (for SEB and
medium alone) or day 5 (KLH and medium alone). Cells were
harvested 24 h later onto glass fibre filter mats (ICN Biomedicals,
Aurora, OH, USA), and incorporated
3H-thymidine was mea-
sured in a liquid scintillation counter. To facilitate the comparison
of proliferative responses, SIs were calculated by dividing the
mean counts per minute (cpm) of triplicates of antigen-containing
wells by the mean cpm of triplicate wells with unstimulated
PBMCs.
Additionally, CFSE (Invitrogen/Molecular Probes, Karlsruhe,
Germany) assays were used to determine proliferation. PBMCs at
1610
7 cells/ml were stained with 0.25 mM CFSE in pre-warmed
PBS for 15 min at 37uC, washed in medium, incubated in pre-
warmed medium for another 30 min, and washed again. The cells
were then adjusted to 1610
6 cells/ml and cultured in medium
with or without SEB or KLH as described above or and incubated
for 6 to 7 days. Alternatively, cells were incubated at 1.25 mg/ml
with HPV16 VLPs or an unrelated control antigen, i.e., mouse
norovirus VLPs similarly produced as the HPV antigen (A447), at
the same dose. After 7 days cells were harvested and washed in
PBS/5% FCS/0.05% sodium azide, stained with anti-CD3
PerCP- and anti-CD4 APC-conjugated mAbs, washed, and fixed.
T cell proliferation was assessed as the percentage of CFSE
low
cells, gating on live CD3
+CD4
+ or CD3
+CD4
2 cells (Figure 1A).
Alternatively, cells were re-stimulated with eight pools of HPV16-
specific, 15mer peptides (124 peptides, pool 1–4 with 16 peptides
each, pool 5–8 with 15 peptides each), 2 mg/ml SEB, or medium
alone in the presence of 1 mg/ml co-stimulatory mAbs CD28 and
CD49d (BD Pharmingen) for 6 h, and Brefeldin A (Sigma) was
added at a final concentration of 10 mg/ml for the last 4.5 h. Cells
were then washed in PBS/5% FCS/0.05% sodium azide, stained
with anti-CD3 PerCP- and anti-CD8 APC-conjugated mAbs,
washed, fixed with 4% paraformaldehyde, and stained with PE-
conjugated mAbs against IFN-c after cell permeabilization with
0.5% saponin in PBS/5% FCS/0.05% sodium azide. T cell
proliferation was assessed as the percentage of CFSE
low cells,
gating on live CD3
+CD8
+ or CD3
+CD8
2 cells, and IFN-c
secretion was measured as the percentage of PE-stained, CFSE
low
cells in the gated cell populations.
ELISPOT assays were preformed using commercially available
reagents (Mabtech AB, Hamburg, Germany) as previously
described [90]. Briefly, PBMCs were resuspended in culture
medium and seeded at 1610
5 cells/well in 96-well plates (MAIP
S4510, Millipore, Schwalbach, Germany), which had been coated
with 1 mg/well of anti-human IFN-c monoclonal antibody
overnight at 4uC. For antigen stimulation, HPV16 L1 protein or
control antigen (A447) was added at 1.25 mg/ml to the wells in
triplicates. Positive and negative controls consisted of cells
stimulated by SEB (1 mg/ml, Sigma) and cells kept in medium
alone. After 20 h of incubation at 37uCi n5 %C O 2, cells were
removed and biotinylated anti-human IFN-c detector antibody
was added (0.1 mg/well), followed by the addition of streptavidin-
alkaline phosphatase conjugate at 1:1000 in PBS/0.1% FBS. Spots
were developed with NBT/BCIP solution (25 mg NBT and 15 mg
BCIP in 0.1 M Tris–HCl pH 9.5 per well) for 30 min, the wells
were washed with distilled water and air-dried, and spots were
counted using a BIOSYS2000 ELISPOT reader. The counts were
extrapolated to 10
6 PBMCs. Average spot numbers of background
Figure 7. Monkey DCs secrete CXCL10 upon stimulation with
poly ICLC. Monocyte-derived DCs were generated from rhesus
macaque CD14
+ monocytes and either stimulated with poly ICLC at
the indicated concentrations or left in medium alone. CXCL10
concentrations in the supernatants collected 48 hours later were
determined by ELISA. Results of seven independent experiments are
given, the horizontal lines indicate the mean concentrations.
doi:10.1371/journal.ppat.1000373.g007
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considered positive responses.
Measurement of antibody responses by ELISA
The presence of L1-specific IgG antibodies in plasma samples
from immunized monkeys was determined by VLP-ELISA as
described earlier [56]. Briefly, 96-well plastic plates were coated
overnight at 4uC with VLP produced in baculovirus infected High
Five insect cells and purified according to a previously published
method [89]. After washing with PBS-T, plates were blocked with
MPBS-T (5% skim milk in PBS- 0–05% Tween) for 1 hr at 37uC.
Prediluted sera (in two-fold dilutions starting from 1:50 to
1:819,200) were added, and plates were incubated for 1 hr at
37uC. After washing, plates were incubated for 1 hr at 37uC with
1:2000 diluted HRP-coupled antihuman IgG F(ab’)2 secondary
antibody (Dianova, Germany) in MPBS-T, TMB (3,39,5,5 -
tetramethylbenzidine) substrate solution (Sigma, Germany) was
used as substrate. OD was measured in an ELISA reader at
450 nm after 10 min and 30 min incubation at room temperature.
Nonspecific binding was determined by using the same dilutions
on plates coated with extracts of High Five cells infected with wt
baculovirus. IgG titers were expressed as the reciprocal of the
highest dilution giving an absorbance above the cut off value (the
average of the negative controls plus three times standard
deviation).
Pseudovirion-based neutralization assay [91]
Pseudovirions were prepared by transfecting 293TT cells
(cultivated in DMEM containing 50 mg of hygromycin/ml) with
a plasmid coding for the humanized HPV16 L1 and L2 genes,
together with a plasmid containing the gene for secretable alkaline
phosphatase (SEAP) under the control of the CMV promoter. For
pseudovirion extraction, cells were harvested 3–4 days later by
trypsination, washed once with PBS and resuspended in 1 ml PBS
containing 1 mM CaCl2 and 5.6 mM MgCl2 per 5610
7 cells and
lysed by 50 ml Brij58 (Sigma) in the presence of Benzonase (250
U/ml) for 5 min on ice. The cellular lysate was centrifuged after
the addition of NaCl to a final concentration of 710 mM, and the
cleared supernatant containing the pseudovirions was used for
infection of 293TT cells. For this purpose, pseudovirions were
diluted 1:5000 in DMEM and preincubated with the sera (dilution
from 1:50 to 1:100,000) for 15 min at room temperature.
Pseudovirions were then added to the cells, followed by incubation
at 37uC for 5 days. Detection of SEAP activity in cell culture
supernatant was measured by using a commercial assay (Roche,
Mannheim, Germany) according to the manufacturer’s recom-
mendations.
Chemokine and cytokine secretion
Chemokine and cytokine concentrations in serum or plasma
samples and cell culture supernatants were measured using ELISA
kits for human CXCL10, CXCL9 (both R&D Systems, Wiesba-
den, Germany), CCL3 (Antigenix America, Huntington, NY,
USA), IFN-a (PBL, Brunswick, USA) [14], IL-17 (eBioscience,
NatuTec, Frankfurt/Main, Germany) [57], and human TNF as
well as monkey IFN-c, IL-4, and IL-12p40 (all U-Cytech, Utrecht,
The Netherlands).
Immunohistochemistry
Cryostat sections were cut, fixed in acetone for 30 min and
incubated with monoclonal antibodies against human CD1a
(dilution: 1:100; Medac, Hamburg, Germany), CD83 (dilution:
1:100) or CD208 (1:70; both Immunotech, Hamburg Germany).
Antibody binding was visualized by the alkaline phosphatase anti-
alkaline phosphatase method using New Fuchsin as chromogen.
The sections were counterstained with hemalaun and mounted.
The numbers of DCs were quantified with a Zeiss AxioImager M1
microscope (Carl Zeiss, Jena, Germany). Using a 406objective, a
standard area was set (unit area). Ten non-overlapping unit areas
were selected. The positive cells were counted using AxioVision
(Release 4.6) software (Zeiss). The values were averaged to
represent the numbers of positive cells per unit area. Due to
inadequate immunohistochemical staining the draining lymph
node from animal number 13408 was omitted from the
examination.
Immunohistochemistry on paraffin sections was performed as
previously described [92]. The following antibodies diluted in
antibody diluent (S3022, DAKO, Glostrup, Denmark) were used:
mouse anti-CXCL10 (MAB266, R&D Systems, 1 mg/ml), goat
anti-CXCL9 (AF392, R&D Systems, 1 mg/ml), and goat anti-
CCL21 (AF366, R&D Systems, 1 mg/ml). After over night
incubation, sections were washed and incubated with rabbit
anti-mouse (E0413, DAKO) or rabbit anti-goat (E0466, DAKO,)
biotinylated antibodies followed by streptavidin-alkalyne phospha-
tase complex (K0391, DAKO), following the manufacturer’s
instructions. Positive cells were detected using New Fuchsin
(K0698, DAKO) as substrate, and tissue sections counterstained
with Meyer’s Haematoxylin (1.09249, Merck, Zug, Switzerland).
In situ hybridization
35S-labeled sense and antisense CXCL9, CXCL10, and CCL21
mRNA probes, 411 bp in length corresponding to position 26 to
437 of the CXCL9 sequence (NM_002416), 372 bp corresponding
to position 28 to 400 of the CXCL10 sequence (NM_001565), and
367 bp corresponding to position 27 to 394 of the CCL21
sequence (NM_002989), respectively, were generated by in vitro
transcription (Roche Molecular Biochemicals, Indianapolis, IN).
Tissue sections were dewaxed, rehydrated in graded ethanol
solutions, and subjected to in situ hybridization, according to a
previously described method [93]. Finally, the sections were
dipped in photo emulsion NTB-2 (Kodak, Rochester, NY) and
exposed in complete darkness for 2 to 4 weeks at 4uC.
Development and fixation were performed according to the
instructions provided by Kodak, and counterstaining was done
with haematoxylin.
Generation of monocyte-derived DCs
Rhesus macaque monocyte-derived DCs were generated from
heparinized peripheral blood as previously described [57]. CD14
+
monocytes were magnetically separated (Miltenyi Biotec, Bergisch-
Gladbach, Germany) and cultured at 1.5–2610
6 cells/3 ml in
RPMI 1640, supplemented with 5% human AB serum (PAN
Biotech, Aidenbach, Germany), human rGM-CSF (1000 U/ml,
sargramostim, Leukine, Berlex, Richmond, CA, USA), human
rIL-4 (100 U/ml, R&D Systems, Wiesbaden-Nordenstadt, Ger-
many, and L-glutamine, 2-mercaptoethanol, HEPES, and peni-
cillin-streptomycin as described under T cell assays. At day 6, DCs
at 1610
5/well were stimulated for 48 h with 50 or 200 mg/ml
poly ICLC in 96-well round bottom plates. Supernatants were
harvested for analysis of cytokine and chemokine secretion.
Statistical analysis
Data are expressed as means6standard error of the mean
(SEM), standard deviation (SD), or median, where appropriate.
Statistical significance of differences was determined by Student’s
t-test or Mann Whitney U-test. Differences were considered
statistically significant for p,0.05.
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Figure S1 Kinetics of proliferative responses in PBMCs after
immunization with KLH and dsRNA. Rhesus macaques were
immunized with KLH plus 0.5 mg/kg poly ICLC (A), KLH plus
0.5 mg/kg poly I:C (B), or KLH alone (C), and cellular immune
responses were determined in proliferation assays. PBMCs were
stimulated for 5 days with KLH (100 mg/ml), and 3H-thymidine
was added for another 24 hours before measuring its incorpora-
tion. Stimulation indices were calculated for results of the
individual animals (marked by the four- or five-digit numbers)
by dividing the mean cpm of triplicates of antigen-containing wells
by the mean cpm of triplicate wells with unstimulated PBMCs.
Found at: doi:10.1371/journal.ppat.1000373.s001 (0.73 MB TIF)
Figure S2 The adjuvant effect of dsRNA on KLH-specific
proliferative immune responses is dose-dependent. Rhesus ma-
caques were immunized with KLH (200 mg) plus poly ICLC at
0.5 mg/kg body weight (A) or 0.1 mg/kg (B) at weeks 0 and 14
(arrows), and KLH-specific proliferation of CD3
+CD4
+ T cells
(solid lines) or CD3
+CD4
2 T cells (dotted lines) was assessed in
CFSE dilution assays, incubated for 7 days. KLH-specific
proliferation was measured as the proportion of CFSElow cells,
gating on CD3-, CD4-double positive or CD3-positive, CD4-
negative cells, respectively. Background proliferation in medium
alone was subtracted from proliferation of KLH-stimulated
PBMCs. The five-digit numbers are monkey designations.
Found at: doi:10.1371/journal.ppat.1000373.s002 (0.74 MB TIF)
Figure S3 Correlation between antibody titers measured by
ELISA and neutralization assays. Titers in serum samples
collected 12 weeks after the first immunization with HPV16
capsomeres (10 mg/animal) alone or together with 2 mg of poly
ICLC or CpG-C are shown for the individual animals.
Neutralization titers are given as reciprocal of the highest dilution
used in this experiment yielding $50% neutralizing activity.
Determination of ELISA titers is described in Materials and
Methods.
Found at: doi:10.1371/journal.ppat.1000373.s003 (0.76 MB TIF)
Figure S4 DC numbers in draining lymph nodes 18 hours after
immunization of KLH plus poly ICLC. Numbers of CD1a, CD83,
and CD208 positive cells per unit area were determined by
immunohistochemistry in lymph node sections before and
18 hours after immunization with KLH plus poly ICLC at
0.5 mg/kg body weight (filled symbols) or 0.1 mg/kg (open
symbols).
Found at: doi:10.1371/journal.ppat.1000373.s004 (0.37 MB TIF)
Table S1 Maximum proliferative responses (mean cpm of wells
in triplicates) after immunization of rhesus macaques with KLH
(200 mg) alone or together with poly I:C or poly ICLC (0.5 mg/kg
body weight).
Found at: doi:10.1371/journal.ppat.1000373.s005 (0.02 MB
DOC)
Table S2 Individual titers of L1-binding antibodies after
immunization with HPV16 capsomeres (10 mg) alone or together
with poly ICLC or CpG-C (2 mg/animal).
Found at: doi:10.1371/journal.ppat.1000373.s006 (0.04 MB
DOC)
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